Page last updated: 2024-12-06

2-tetradecylglycidic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-tetradecylglycidic acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71976
CHEMBL ID12394
SCHEMBL ID1579204
MeSH IDM0077041

Synonyms (33)

Synonym
mcn-3802
acido palmoxirico [spanish]
acide palmoxirique [french]
acidum palmoxiricum [latin]
palmoxiric acid [inn]
palmoxirate acid
palmoxiric acid
2-tetradecyloxiranecarboxylic acid
2-tetradecylglycidic acid
mcn 3802
CHEMBL12394 ,
2-tetradecyloxirane-2-carboxylic acid
2-tetradecyl-2-oxiranecarboxylic acid
68170-97-8
(+/-)2-tetradecyl-oxirane-2-carboxylic acid
2-tetradecyl-oxirane-2-carboxylic acid
bdbm50024431
(+-)-2-tetradecyl-2-oxiranylcarbonsaeure
acide palmoxirique
acidum palmoxiricum
r326x4trby ,
unii-r326x4trby
acido palmoxirico
gtpl2683
(plusmn) acid 3
oxiranecarboxylic acid, 2-tetradecyl-, (+/-)-
2-oxiranecarboxylic acid, 2-tetradecyl-
(+/-)-2-tetradecylglycidate
palmoxirate
oxiranecarboxylic acid, 2-tetradecyl-
SCHEMBL1579204
Q27088241
DTXSID00867519

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" To circumvent the effects of LCFAO inhibition, diabetic mice were dosed with TDGA and given a diet containing 9% octanoic acid."( Prevention of the metabolic effects of 2-tetradecylglycidate by octanoic acid in the genetically diabetic mouse (db/db).
Bahl, JJ; Bressler, R; Lee, SM, 1985
)
0.27
" Drug-treated animals had significant lowering of fasting glucose at 0 and 4 h after dosing during the midportion of the study (2-6 wk)."( Metabolic control of prevention of nephropathy by 2-tetradecylglycidate in the diabetic mouse (db/db).
Bressler, R; Kircher, CH; Lee, SM; Tutwiler, G, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.90000.00051.48357.8000AID46869
Carnitine O-palmitoyltransferase 1, liver isoform Rattus norvegicus (Norway rat)IC50 (µMol)0.04000.04000.06500.0900AID219026
Carnitine palmitoyl transferase I liver isoform Sus scrofa (pig)IC50 (µMol)0.90000.30000.60000.9000AID46869
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID179249In vitro inhibition of palmitate oxidation1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Alkylglycidic acids: potential new hypoglycemic agents.
AID194312Rat glucose tolerance test was determined in vivo at 100 mg/kg perorally1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Resolution of (+/-)-2-tetradecyloxiranecarboxylic acid. Absolute configuration and chiral synthesis of the hypoglycemic R enantiomer and biological activity of enantiomers.
AID179589In vitro inhibition of [1-14C]palmitate oxidation in rat hemidiaphragms1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Resolution of (+/-)-2-tetradecyloxiranecarboxylic acid. Absolute configuration and chiral synthesis of the hypoglycemic R enantiomer and biological activity of enantiomers.
AID184484Compound was tested in vitro for inhibition of palmitate oxidation1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Alkylglycidic acids: potential new hypoglycemic agents.
AID184857Minimum effective concentration by rat glucose tolerance test (po)1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Alkylglycidic acids: potential new hypoglycemic agents.
AID219026Inhibition of carnitine palmitoyl transferase (CPT), assessed with isolated rat liver mitochondria1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Resolution of (+/-)-2-tetradecyloxiranecarboxylic acid. Absolute configuration and chiral synthesis of the hypoglycemic R enantiomer and biological activity of enantiomers.
AID185917Maximum lowering of blood glucose when 100 mg/kg of the drug administered orally was reported by rat glucose tolerance test1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Alkylglycidic acids: potential new hypoglycemic agents.
AID46869Compound was tested for its inhibitory activity against carnitine palmitoyl transferase-A (CPT-A)1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Alkylglycidic acids: potential new hypoglycemic agents.
AID185057Rat glucose tolerance in vivo expressed as minimum effective dose (MED), it is the lowest dose giving a statistically significant (p<0.05) lowering at any time point1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Resolution of (+/-)-2-tetradecyloxiranecarboxylic acid. Absolute configuration and chiral synthesis of the hypoglycemic R enantiomer and biological activity of enantiomers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (74)

TimeframeStudies, This Drug (%)All Drugs %
pre-199044 (59.46)18.7374
1990's22 (29.73)18.2507
2000's7 (9.46)29.6817
2010's1 (1.35)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.62 (24.57)
Research Supply Index4.34 (2.92)
Research Growth Index3.97 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other75 (98.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]